Previous 10 | Next 10 |
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting – October 4-6, 2023 Date: October 5, 2023 Type: Poster Presentat...
2023-09-26 15:08:59 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Novartis and Ionis in pact for new cardiovascular therapy AstraZeneca-Ionis deal for eplontersen expands to Latin America S...
- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing - Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications f...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 18 th Annual BioPharma Conference – September 6, 2023 Type: 1-on-1 Investor Meetings European Respiratory Society (ERS) I...
2023-08-11 11:38:16 ET Summary Arrowhead Pharmaceuticals had a strong financial performance in Q1 2023, a compelling RNAi therapeutic pipeline, and beneficial strategic partnerships. However, the company's recent financial performance in Q2 2023 showed a significant drop in revenu...
2023-08-07 18:35:02 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Conference Call August 07, 2023 04:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San...
2023-08-07 16:40:39 ET Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): Q3 GAAP EPS of -$0.96 misses by $0.37 . Revenue of $15.83M (-51.2% Y/Y) misses by $29.59M . For further details see: Arrowhead Pharmaceuticals GAAP EPS of -$0.96 misses by $0...
Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the...
2023-07-30 06:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund outperformed the broader market in Q2 2023, with a 16.31% retur...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter ended June 30, 2023. Webcast and Conference Call and Details Investors ma...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Arrowhead Pharmaceuticals Inc. Website:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may ac...
– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held J...